Agilent Technologies (A) Stock Overview
Provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for A from our risk checks.
A Community Fair Values
Create NarrativeSee what 53 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Agilent Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$144.75 |
| 52 Week High | US$163.75 |
| 52 Week Low | US$108.35 |
| Beta | 1.24 |
| 1 Month Change | -2.67% |
| 3 Month Change | 11.73% |
| 1 Year Change | 16.62% |
| 3 Year Change | 27.61% |
| 5 Year Change | -16.71% |
| Change since IPO | 238.60% |
Recent News & Updates
Recent updates
Narrative Update • Sep 03
A: New Diagnostics And Lab Tools Pipeline Will Drive Future Upside Potential
Analysts have raised their price target on Agilent Technologies from $161 to $174.90, citing updated assumptions for slightly higher revenue growth, profit margins, and future P/E multiples in their models. What’s in the News for Agilent Technologies Agilent Technologies launched the Cary 635 FTIR spectrometer, a compact Fourier transform infrared system designed to support efficient, flexible analytical workflows across multiple lab applications.Analysis Article • Jun 19
Agilent Technologies (A) Stock Could Be 21.1% Undervalued After Earnings Beat And Higher Outlook
Agilent Technologies (A) is back in focus after reporting strong Q2 2026 revenue growth, an earnings beat, and a raised full-year outlook, alongside plans for a China Innovation Center and the Biocare acquisition. See our latest analysis for Agilent Technologies. Agilent Technologies’ recent earnings beat and guidance raise appear to have shifted sentiment, with a 30 day share price return of 14.91% and a 1 year total shareholder return of 10.89%, even though the year to date share price...Narrative Update • Jun 06
A: AI Partnerships And New Diagnostics Offer Compelling Future Upside Potential
Analysts have adjusted their price target on Agilent Technologies slightly to $161.00. This reflects updated assumptions around discount rate, long term revenue growth, profit margins and future P/E expectations.Seeking Alpha • May 28
Agilent Technologies: A Solid Q2 Beat, But The Stock Remains A Hold
Summary Agilent Technologies, Inc. posted a strong Q2 2026 quarter, with top and bottom line numbers both exceeding estimates. All segments earned positive growth, with two out of three seeing increases of more than double-digits. Despite the solid quarterly results, I maintain a Hold rating, as A stock appears slightly overvalued and has a forward return potential lower than my benchmark. Read the full article on Seeking AlphaNarrative Update • May 20
A: New Diagnostic Indications And Buybacks Will Support Future Upside Potential
Analysts have nudged their price target on Agilent Technologies slightly higher to $161.07 from $160.69, reflecting modest adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Launched the BioTek Cytation 9 cell imaging multimode reader, combining multimode microplate reading with high content cell imaging in a single platform aimed at faster, higher throughput workflows in research, pharmaceutical, and biotechnology labs (Product related announcement).Narrative Update • Apr 25
A: New Diagnostic Approvals And Buybacks Will Support Long Term Upside
Analysts have trimmed their price target on Agilent Technologies by about $1 to $160.69, reflecting slightly adjusted views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Supreme Court of the United States denied Agilent Technologies' petition related to two CRISPR guide RNA patents, leaving in place prior rulings that found all claims of the patents unpatentable.Narrative Update • Apr 09
A: New Diagnostic Expansion And Guidance Will Support Long Term Upside
Analysts have slightly reduced their price target on Agilent Technologies by about $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. They indicate that the overall outlook remains largely intact.Narrative Update • Mar 26
A: New Diagnostic Approval Will Drive Upside For Long Term Outlook
Analysts have made a slight trim to their price target for Agilent Technologies to about $163.19 from around $163.29, citing updated assumptions for revenue growth, profit margins and a somewhat lower future P/E multiple. What's in the News The FDA approved Agilent's PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to help identify first line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for treatment with KEYTRUDA, adding a seventh companion diagnostic indication for this assay (Key Developments).Narrative Update • Mar 11
A: New Diagnostic Approvals And Digital Pathology Expansion Will Drive Upside
Analysts have trimmed their price target on Agilent Technologies to about $163 from roughly $170, citing modest tweaks to their models, including slightly adjusted revenue growth, discount rate, profit margin, and future P/E assumptions. What's in the News Agilent issued earnings guidance for fiscal Q2 2026, with revenue expected in the range of $1.79b to $1.82b, framed as approximately 7% to 9% reported growth and 4% to 5.5% core growth (company guidance).Narrative Update • Feb 25
A: New Diagnostic Approvals Will Support Measured Upside Ahead
Analysts reaffirm a price target of $169.67 for Agilent Technologies, citing largely unchanged assumptions for the discount rate, revenue growth, profit margin, and future P/E. These factors together keep their valuation framework intact.Narrative Update • Feb 10
A: New Digital Pathology And Board Declassification Will Support Measured Upside Ahead
Analysts have modestly trimmed their price target on Agilent Technologies to reflect slightly higher discount rate assumptions and a lower future P/E, while still incorporating steady revenue growth and a marginally stronger profit margin outlook. What's in the News Agilent plans to ask shareholders at the March 18, 2026 AGM to approve an amendment to its Third Amended and Restated Certificate of Incorporation that would declassify the board of directors over three years, shifting toward annual director elections (Key Developments).Narrative Update • Jan 26
A: New Digital Pathology And Buybacks Will Support Measured Upside Ahead
Analysts have nudged their price target on Agilent Technologies slightly higher to about US$170, citing updated assumptions around fair value, discount rates, revenue growth, profit margins and future P/E, which collectively support a modest upward revision. What's in the News Agilent launched the S540 MD Slide Scanner System for whole slide imaging in key European markets, adding a high throughput digital pathology scanner with capacity for 540 slides and AI assisted tissue detection to its portfolio (Product Related Announcements).Narrative Update • Jan 11
A: New CFO And Capital Returns Will Support Measured Upside Ahead
Analysts have nudged their price target for Agilent Technologies slightly lower to US$168.59 from US$169.44, citing small adjustments to their fair value estimate, discount rate, revenue growth outlook, profit margin assumptions, and future P/E expectations. What's in the News Agilent outlined fiscal first quarter 2026 revenue guidance of US$1.79b to US$1.82b and fiscal 2026 revenue guidance of US$7.3b to US$7.4b, with both ranges expressed in reported and core terms (Corporate guidance).Analysis Article • Dec 18
Agilent Technologies (NYSE:A) Is Increasing Its Dividend To $0.255
Agilent Technologies, Inc. ( NYSE:A ) has announced that it will be increasing its dividend from last year's comparable...Narrative Update • Dec 15
A: New Leadership And Compliance Software Will Support Measured Upside Ahead
Analysts have nudged their average price target on Agilent Technologies higher by about $2 to roughly $169.44, citing slightly faster expected revenue growth and a modestly lower discount rate that more than offset a small downward revision to long term profit margins. What's in the News Launched 21 CFR Part 11 compliant software for the xCELLigence RTCA eSight system, enabling secure deployment in GMP manufacturing and QC labs with features such as secure logins, e-signatures, and full audit trails (Key Developments).Narrative Update • Nov 30
A: New Diagnostic Solutions And Leadership Will Shape Measured Prospects Ahead
Analysts have raised their price target for Agilent Technologies from $152.33 to $167.57, citing modestly higher expectations for revenue growth and valuation metrics as the primary reasons for the change. What's in the News Agilent Technologies provided earnings guidance for fiscal Q1 2026, expecting revenue in the range of $1.79 billion to $1.82 billion, up 6% to 8% reported and 4% to 6% core.Analysis Article • Nov 27
Agilent Technologies, Inc. (NYSE:A) Analysts Are Pretty Bullish On The Stock After Recent Results
It's been a good week for Agilent Technologies, Inc. ( NYSE:A ) shareholders, because the company has just released its...Narrative Update • Nov 16
A: Product Launches And Diagnostic Approval Will Support Balanced Outlook
Narrative Update: Agilent Technologies Analyst Price Target Revision Analysts have raised their price target for Agilent Technologies from $149.90 to $152.33. This change reflects modest upward revisions in projected revenue growth and a slightly higher expected future valuation multiple.Narrative Update • Nov 01
A: Global Healthcare Trends And New Diagnostic Solutions Will Shape Future Performance
Analysts have slightly raised their price target for Agilent Technologies from $148.57 to $149.90, citing stable fundamentals and a modest valuation adjustment. What's in the News Adam S.Narrative Update • Oct 18
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Analysts have raised their price target for Agilent Technologies from $140.97 to $148.57, citing improved revenue growth prospects and higher expected profit margins as key drivers behind the upward revision. What's in the News Announced launch of Insight Series Alarm Resolution Systems, which enhance airport security checkpoints with advanced liquid explosive detection and adaptability to changing regulations (Product Related Announcements).Narrative Update • Oct 04
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Agilent Technologies received a modest analyst price target increase from $138.83 to $140.97. This reflects analysts' expectations for stable growth and slightly improved long-term valuation metrics.Narrative Update • Sep 16
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Agilent Technologies’ fair value estimates have remained stable, as reflected by marginal changes in both the consensus analyst price target (up slightly to $138.83) and the forward P/E (now 27.33x). What's in the News Raised full-year 2025 revenue guidance to $6.91–$6.93 billion, up 6.2–6.5% reported and 4.3–4.6% core, reflecting a $150 million increase at the midpoint and 1.5 points higher core growth.Shareholder Returns
| A | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -4.4% | -1.9% | -0.2% |
| 1Y | 16.6% | 25.5% | 14.8% |
Return vs Industry: A underperformed the US Life Sciences industry which returned 25.5% over the past year.
Return vs Market: A exceeded the US Market which returned 14.8% over the past year.
Price Volatility
| A volatility | |
|---|---|
| A Average Weekly Movement | 4.1% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: A has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: A's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 18,200 | Padraig McDonnell | www.agilent.com |
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems.
Agilent Technologies, Inc. Fundamentals Summary
| A fundamental statistics | |
|---|---|
| Market cap | US$41.40b |
| Earnings (TTM) | US$1.44b |
| Revenue (TTM) | US$7.37b |
28.3x
P/E Ratio5.5x
P/S RatioIs A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A income statement (TTM) | |
|---|---|
| Revenue | US$7.37b |
| Cost of Revenue | US$3.42b |
| Gross Profit | US$3.96b |
| Other Expenses | US$2.52b |
| Earnings | US$1.44b |
Last Reported Earnings
Jul 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.11 |
| Gross Margin | 53.65% |
| Net Profit Margin | 19.53% |
| Debt/Equity Ratio | 53.6% |
How did A perform over the long term?
See historical performance and comparisonDividends
0.7%
Current Dividend Yield20%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/09 13:15 |
| End of Day Share Price | 2026/09/09 00:00 |
| Earnings | 2026/07/31 |
| Annual Earnings | 2025/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Agilent Technologies, Inc. is covered by 39 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Robert Bamberger | Baird |
| Charles Butler | Barclays |